Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma

PURPOSE: To the best of our knowledge, this study is the first to compare dual inhibition of PI3K/mammalian target of rapamycin (mTOR) by apitolisib (GDC-0980) against single inhibition of mTORC1 by everolimus in metastatic renal cell carcinoma (mRCC). PATIENTS AND METHODS: Patients with clear-cell...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Powles, Thomas, Lackner, Mark R., Oudard, Stéphane, Escudier, Bernard, Ralph, Christy, Brown, Janet E., Hawkins, Robert E., Castellano, Daniel, Rini, Brian I., Staehler, Michael D., Ravaud, Alain, Lin, Wei, O’Keeffe, Bridget, Wang, Yulei, Lu, Shan, Spoerke, Jill M., Huw, Ling-Yuh, Byrtek, Michelle, Zhu, Rui, Ware, Joseph A., Motzer, Robert J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2016
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5569691/
https://ncbi.nlm.nih.gov/pubmed/26951309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.64.8808
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados